Wolfe Research Says COVID Uncertainty Continues to Weigh on Pfizer (PFE) Outlook Wolfe Research analyst Alexandria Hammond's decision to raise her price target on Pfizer may have been a welcome boost for investors, but it's tempered by her continued "Underperform" rating on the stock.
Despite the company's latest quarterly earnings report beating expectations, concerns about COVID related uncertainty remain.
During the Q1 2026 earnings call, Pfizer CEO Albert Bourla acknowledged that recent settlement agreements related to patent infringement claims involving Vyndamax won't have a significant effect on the company's growth profile until at least 2028.